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ORIGINAL ARTICLE
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ABSTRACT
Oral bisphosphonates are the primary medication for osteoporosis, but concerns exist regarding potential bone-quality changes or
low-energy fractures. This cross-sectional study used artiﬁcial intelligence methods to analyze relationships among bisphosphonate treatment duration, a wide variety of bone-quality parameters, and low-energy fractures. Fourier transform infrared spectroscopy and histomorphometry quantiﬁed bone-quality parameters in 67 osteoporotic women treated with oral bisphosphonates for
1 to 14 years. Artiﬁcial intelligence methods established two models relating bisphosphonate treatment duration to bone-quality
changes and to low-energy clinical fractures. The model relating bisphosphonate treatment duration to bone quality demonstrated optimal performance when treatment durations of 1 to 8 years were separated from treatment durations of 9 to 14 years.
This may be due to a change in relationship of bone-quality parameters with treatment duration. This model also showed that the
effects of bisphosphonate treatment duration were most highly correlated with changes in means and standard deviations of
infrared spectroscopically derived mineral and matrix parameters and histomorphometric bone turnover parameters. A second
model related treatment duration to bone fracture in all 22 patients who fractured while on treatment with bisphosphonates
for more than 8 years. This second model showed that bisphosphonate treatment duration, not hip bone mineral density
(BMD), was the most strongly correlated parameter to these low-energy bone fractures. Application of artiﬁcial intelligence
enabled analysis of large quantities of structural, cellular, mineral, and matrix bone-quality parameters to determine relationships
with long-term oral bisphosphonate treatment and fracture. Infrared spectroscopy provides clinically relevant bone-quality information of which bone mineral purity is among the most relevant. Nine or more years of bisphosphonate treatment was associated
with abnormal bone mineral purity, matrix abnormalities, and low-energy fractures. These data justify limiting bisphosphonate
treatment duration to 8 years. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society
for Bone and Mineral Research.
KEY WORDS: BONE QUALITY; OSTEOPOROSIS; BISPHOSPHONATES; DXA; FRACTURE RISK ASSESSMENT

1. Introduction

O

steoporosis is a health problem of major proportions. It
affects more than 200 million people worldwide, results in
more than 2 million fractures annually in the US, and hospital
admissions for osteoporotic fractures exceed those of heart
attacks, strokes, and breast cancer combined.(1–3) Osteoporotic
fractures may occur because of loss of bone quantity and—less
widely recognized—unfavorable changes to bone quality.(4,5)
Bisphosphonates are the primary modality for treating postmenopausal osteoporosis; their effectiveness is due to reduction of

osteoclastic activity accompanying high bone turnover.(6) Concerns exist that bisphosphonate use may be associated with
bone-quality changes that reduce load-bearing mechanical
competence and this may partially explain reported occurrences
of low-energy fractures accompanying long-duration bisphosphonate use.(7) These reports dampen the enthusiasm of
patients and physicians for use of bisphosphonates to treat
osteoporosis.
Evidence supporting the hypothesis of a relationship between
long-term bisphosphonate use and bone-quality changes was
provided in our prior studies of bone structure(8) and mechanical
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properties.(9) These structural and material property changes
may be the manifestation of bisphosphonate-related changes
in bone cell activity and bone mineral or matrix structural or
compositional changes. Support for this hypothesis is found in
other studies suggesting changes in relative mineralization, crystallinity, and crystal size or collagen cross-linking with bisphosphonate use.(10,11) This is shown through changes in the
distribution, but not mean values, of these parameters with varying bisphosphonate treatment duration. This may be due to
method of analysis, small numbers of study patients, limited
treatment duration, or small changes in bone-quality parameters
with bisphosphonate treatment duration.(12) Furthermore, the
relationship between bisphosphonate treatment duration and
low-energy bone fractures is also unclear. Thus, the objectives
of this study were to: (i) evaluate structural, cellular, turnover,
mineral and matrix parameters of bone, and relevant patient
data and their relationship with 1 to 14 years of bisphosphonate
treatment duration and (ii) to determine relationships between
bone fracture and structural, cellular, turnover, mineral and
matrix parameters of bone, relevant patient data, and bisphosphonate treatment duration.

2.

Materials and Methods

2.1

Study design

Relationships among bone mineral, matrix, structural, and
dynamic properties with continuous oral bisphosphonate treatment duration were evaluated from human anterior iliac crest
bone samples using histomorphometry and Fourier transform
infrared spectroscopy (FTIR) with a cross-sectional design. FTIR
is an established technique for analyzing various tissues in health
and disease; it is especially useful for quantifying various bone
mineral and matrix parameters reﬂecting bone quality and fracture resistance.(13–16) Bone mineral parameters included mean
values and standard deviations of the mineral to matrix ratio, carbonate to phosphate ratio, and c-axis mineral crystal length
(crystallinity). The bone matrix parameter was the ratio of mature
to immature collagen cross-links (cross-linking ratio).
Histomorphometric-based bone structure parameters were
bone volume/tissue volume, trabecular separation, and trabecular thickness. Histomorphometric-based bone formation parameters were osteoid volume/bone volume, osteoid surface/bone
surface, osteoid thickness, number of osteoblasts/bone perimeter, erosion surface/bone surface, number of osteoclasts/bone
perimeter, mineral apposition rate, mineralizing surface/bone
surface, bone formation rate/bone surface, mineralization lag
time, and activation frequency. Clinical and biochemical data
were obtained from the patient’s medical records available at
time of biopsy and were also stored in the Kentucky Bone Registry. Design of this study conformed to the Declaration of Helsinki
and was approved by the University of Kentucky Institutional
Review Board.

evaluation to decide optimal therapy continuation. These
patients were previously diagnosed by dual-energy X-ray
absorptiometry (DXA) of the femoral neck or lumbar spine or
by low-energy fracture regardless of DXA score and were offered
a minimally invasive anterior iliac crest bone biopsy with double
tetracycline labeling for workup of turnover for choice of therapy. Bone biopsies are routinely offered by our clinic to all
patients with metabolic bone disorders; approximately 85%
agree to the biopsy. All study patients signed an Institutional
Review Board–approved consent form permitting their results
to be used for subsequent scientiﬁc studies. Low-energy fractures were deﬁned as radiologically observed fractures occurring
in the absence of documented trauma.

2.3

The inclusion criteria were adult (age older than 21 years) female
patients with osteoporosis who were treated with oral bisphosphonates for at least 1 year and had veriﬁed intake of doubletetracycline labeling. The exclusion criteria were genetic diseases
(such as osteogenesis imperfecta, hypophosphatemic rickets,
etc.), chronic kidney or liver diseases, primary hyperparathyroidism, neoplasms, or previous treatment with medications known
to alter bone metabolism (except oral bisphosphonates).
Patients presently or previously treated with anticonvulsants or
long-term steroids or those with documented chronic alcoholism, drug addiction, malabsorption, malignancy, bariatric surgery, Paget’s disease, osteogenesis imperfecta, hemiplegia or
paraplegia, organic illness with potential inﬂuence on bone
metabolism, or uncontrolled systemic illness were also excluded.

2.4

Patients

This was a retrospective cross-sectional study of bone samples
selected from among a population collected from the past three
decades and stored in the registry. The included bone samples
were from a consecutive series of adult female patients with
osteoporosis previously treated with oral bisphosphonates (alendronate, risedronate, or ibandronate) who presented to the University of Kentucky Metabolic Bone Disease Clinic for turnover
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Bone biopsy, histology, and histomorphometry

Before bone biopsy, patients received oral demeclocycline
hydrochloride (300 mg) twice daily for 2 days, followed by a
10-day tetracycline-free interval and another course of tetracycline hydrochloride (250 mg) twice daily for 4 days. Anterior iliac
crest bone biopsies were performed under local anesthesia after
an additional 4 days. Iliac crest bone samples were ﬁxed with
ethanol at room temperature, dehydrated, and embedded in
polymethylmethacrylate as described previously.(17) Serial sections of 3-μm and 7-μm thickness were cut with a microtome
equipped with a carbide-edged knife. Sections were stained with
modiﬁed Masson-Goldner trichrome stain. Unstained sections
were prepared for phase-contrast and ﬂuorescence light microscopy. Bone histomorphometry for static and dynamic parameters of bone structure, formation, and resorption was
performed at a magniﬁcation of 200 using the Osteoplan II system (Carl Zeiss, New York, NY, USA). All measured histomorphometric parameters complied with the recommendations of the
nomenclature committee of the American Society for Bone and
Mineral Research.(18,19)

2.5
2.2

Inclusion and exclusion criteria

Infrared spectroscopy

Two to ﬁve 4-μm-thick sections were cut from each embedded
bone sample, and each section was individually sandwiched
between two barium ﬂuoride discs. The sandwiched sample
was placed on the stage of a Nexus 6700 Fourier Transform Infrared Spectrometer (Thermo Electron, Waltham, MA, USA). Infrared
spectra were collected over most of the trabecular bone area of
each sample using an automated routine. Separate background
scans were done to enable spectral subtraction and correction of
JBMR Plus (WOA)

errors attributable to the environment, BaF discs, and embedding material.(20)

2.6 Fourier transform infrared spectroscopic image
analysis
Analysis of these spectroscopic images began by automated
identiﬁcation of the area of bone scanned by the infrared beam.
This area was deﬁned as the sum of 6 μm  6 μm scanned pixels.
Location of these pixels were determined from a grid established
by passing a straight line along the longitudinal axis of the trabeculum and then arranging a series of parallel lines spaced 6 μm
apart along this line. These parallel lines ranged in length from
one edge of a trabeculum to the opposite edge of the same trabeculum within the ﬁeld of view (Fig. 1). Values for the mineral
and matrix response parameters, ie, mineral to matrix ratio, carbonate to phosphate ratio, c-axis mineral length, and crosslinking ratio, were calculated from the scans taken in the area
deﬁned by these lines (Fig. 1). These values were determined
for each 6 μm  6 μm area on the surface of each examined trabeculum using reported techniques.(20) Mean values and standard deviations of each spectroscopic parameter within each
sample were determined. Approximately 325 individual bone
areas, each 6 μm  6 μm, were scanned per patient.

Fig 1. Mineral to matrix ratio on trabecular bone surface. Representative
surface of a single trabeculum and grid guiding systematic Fourier transform infrared spectroscopic (FTIR) measurements. Variations in the mineral to matrix ratio (the bone mineral quality parameter shown) are
denoted using different color shades. Dark red denotes bone surface
with high mineral to matrix ratio; light orange denotes bone surface with
low mineral to matrix ratio. The thin dark line deﬁning the longitudinal
axis of the trabeculum references subsequently constructed multiple
orthogonal lines along which FTIR scans were made each 6 μm. Red
and green circles denote trabecular boundaries. Background area (white
region) was excluded. All mineral and matrix properties were measured
along the orthogonal lines with a 36-μm square area resolution.
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Measured mineral and matrix parameters were divided into
low, medium, or high categories. Thresholds for these categories
were as follows: Low were those values less than the mean value
of the lower half minus 1 SD, high were those greater than the
mean value of the greater half plus 1 SD, and the medium category consisted of all measurements above low but below high.
Speciﬁc values denoting the low or high thresholds are shown
for each of the mineral and matrix parameters (Table 1).
The total area of trabecular bone scanned by the infrared
beam was calculated for each sample. The mean value of each
parameter in each category (Table 1) was normalized by the total
bone area from which that value was obtained. Mean and standard deviations of these area-normalized values were then
determined. The analyses extracted a total of 44 infrared
spectroscopy-based parameters and 12 histomorphometric
parameters. These parameters were analyzed using statistical
methods and machine-learning modeling to quantify the relationship between bone quality and bisphosphonate treatment
duration.

2.7 Statistics and machine-learning modeling
The goal of machine-learning techniques was to generate the
best prediction of an independent variable from a variety of
dependent variables. Once a satisfactory prediction was
obtained, machine-learning methods were then used to identify
the parameters that contributed most to model performance.
Statistical and machine-learning analyses used these infrared
spectroscopy, histomorphometry, and patient-based parameters
to understand relationships among bone quality, bisphosphonate treatment duration, and fracture. Two computational challenges were addressed. The ﬁrst challenge arose from the
disparity between the large number of parameters analyzed
compared with the number of study subjects. This disparity frequently leads to the computationally difﬁcult(21) problem of data
overﬁtting that besets construction of robust machine-learning
models. To overcome this challenge, XGBoost, an established
and optimized distributed gradient boosting algorithm,(22) was
adapted from the library of R statistical software.(23) By implementing conventional machine-learning algorithms under the
Gradient Boosting framework,(24) XGBoost offered superior regularized model formalization to control overﬁtting and was thus
capable of providing parallel-tree boosting that effectively solves
this challenge. Before employing XGBoost, a minimum redundancy/maximum relevance feature reduction method (mRMR)
was used to identify the most critical features in each candidate
model based upon the data.(25)
The second challenge arose from the lack of a uniform or normally distributed bisphosphonate treatment duration (Fig. 2).
Clearly, more patients were treated for short durations compared
with those treated for long durations. Although a slight imbalance is generally of no concern, challenges arise in machinelearning if imbalances in the data are substantial. This challenge
was resolved using repetitive random down-sampling(26) to generate a balanced set (equal numbers of patients in each bisphosphonate treatment duration category) of training data from the
original data set. Cross-validation was used to reduce random
effect. Data analysis was performed using R version 3.6.3
(R Foundation for Statistical Computing) and the R package
XGBoost. Model parameters were tuned using the caret package
in R.
To support the applicability of the sample size used and the
generalizability of the models developed, the effort focused on
BISPHOSPHONATE AND BONE QUALITY IN FRACTURES
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Table 1. Threshold Values for Categorization of FTIR Parameters
FTIR parameter

Low category
threshold

High category
threshold

3.580
0.008

5.230
0.010

1.072

1.164

3.065

3.769

Mineral to matrix ratio
Carbonate to
phosphate ratio
C-axis mineral crystal
length
Cross-linking ratio

FTIR = Fourier transform infrared spectroscopy.

separated by varying treatment durations. The separation point
distinguishing these two categories varied from 5 to 9 years. Fit
of this model, assessed using the area under the curve (AUC) of
the receiver operating characteristic (ROC) metric, was optimized
(AUC = 0.88) when the bisphosphonate treatment duration categories were distinguished at the 8-year time point (Table 3).
That is, the relationship between changes in bone-quality
parameters and bisphosphonate treatment duration was optimal when treatment duration was separated into two categories,
ie, from 1.1 years to the end of 8 years and 9 years to the maximum of 14 years.
The second step of this process involved use of the identiﬁed
optimal two duration categories, 1 to 8 and 9 to 14 years of
bisphosphonate treatment. The bone-quality machine-learning
model was then optimized by sequential inclusion of various
infrared spectroscopic and histologic bone-quality parameters
as well as various patient parameters (Table 4). Differentiation
between the resulting models was then accomplished using
the AUC metric. The results showed that the best performance
(AUC = 0.90) was obtained using three different types of parameters: Two were infrared spectroscopic and histomorphometric
and one was a patient-speciﬁc parameter (bone mineral density
[BMD] hip). The results of these sequential analyses are shown in
ascending order (Table 4).

3.2
Fig 2. Distribution of bisphosphonate treatment durations among the
study subjects.

bone-quality parameters with minimum redundancy and maximum relevance. In addition, the XGBoost model was made more
conservative by restricting the maximum depth of trees, tuning
the XGBoost parameters γ and η to minimize loss reduction
and step size shrinkage, as well as utilizing L1 and L2 regularization techniques.

3.

Results

3.1

Subjects

Pertinent characteristics of the 67 included study patients are
shown (Table 2). Analysis of the relationships between bonequality changes and bisphosphonate treatment duration was
non-trivial due to the plethora of data obtained. For this reason,
a meta-analysis machine-learning model was developed using a
two-step process. The ﬁrst step involved consideration of the
range of observed bisphosphonate treatment durations as a
two-category discrete variable in which the categories were

Machine-learning duration model

The relationship between bisphosphonate treatment duration
and all infrared spectroscopic, histomorphometric, and patientrelated parameters were analyzed using machine-learning
(Supplemental Fig. S1). Only those parameters with estimated
linear coefﬁcients exceeding 0.2 were retained in a model linking
bisphosphonate treatment duration with bone quality. The
retained parameters include parameters of mineral perfection,
collagen maturity, histologic cell and turnover parameters, and
BMD of the hip (Fig. 3).
Two of the parameters shown in Fig. 3 express changes in
mean values of bone mineral parameters and two parameters
express changes in mean values or standard deviations of bone
matrix parameters. Examples of actual infrared spectroscopic
images from which bone mineral and matrix quality data were
obtained, ie, the carbonate to phosphate ratio and matrix maturity (ratio of mature to immature collagen cross-links) are shown
(Figs. 4A, B and 5A, B).

3.3

Machine-learning fracture model

Twenty-two(22) study patients sustained nontraumatic fractures
during bisphosphonate treatment (Tables 5 and 6). Machinelearning methods were again employed to analyze the relationship between all studied bone parameters and bisphosphonate
treatment in these 22 patients. The presence or absence of bone

Table 2. Pertinent Characteristics of the 67 Study Subjects at Time of Iliac Crest Bone Biopsy
Age (years)
BMD spine (t value)
BMD hip (t value)
Body mass index
Duration of bisphosphonate treatment (years)

Mean

Standard deviation

Median

Minimum

Maximum

60
2.48
1.90
25.08
5.60

8
0.97
0.88
5.13
2.95

59.00
2.50
2.05
23.51
5.00

34
4.20
4.10
15.96
1

77
0.70
1.00
43.53
14

BMD = bone mineral density.
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Table 3. Model Performance Resulting From a Meta-Analysis Relating Bone Parameters to Bisphosphonate Treatment Duration
Bisphosphonate treatment
duration categories (years)
1–5 and 6–14
1–6 and 7–14
1–7 and 8–14
1–8 and 9–14
1–9 and 10–14

Model ﬁt parameters

First treatment period

Second treatment period

AUC

Accuracy

Precision

Sensitivity

F-1

Precision

Sensitivity

F-1

0.71
0.75
0.77
0.88
0.82

0.71
0.73
0.76
0.87
0.89

0.77
0.70
0.92
0.93
0.88

0.59
0.79
0.59
0.82
0.90

0.67
0.74
0.71
0.86
0.89

0.67
0.77
0.69
0.84
0.91

0.82
0.67
0.94
0.92
0.88

0.74
0.71
0.80
0.87
0.89

AUC = area under the receiver operating characteristic curve.
F-1 denotes the harmonic mean of precision and sensitivity. Bone parameters used in the model consist of infrared spectroscopic parameters, histomorphometric parameters, and body mass index. Boldface denotes treatment duration categories with optimal model performance.

Table 4. Results of Candidate Machine-Learning Models Relating Categorical Bisphosphonate Treatment Duration to the Various Parameter Types Shown
Model ﬁt
parameters

First treatment period

Second treatment period

Parameter type

AUC

Accuracy

Precision

Sensitivity

F-1

Precision

Sensitivity

F-1

Histomorphometry
Infrared spectroscopy
Infrared spectroscopy and histomorphometry
Infrared spectroscopy, histomorphometry, and
patient age
Infrared spectroscopy, histomorphometry, and
patient BMI
Infrared spectroscopy, histomorphometry, and
patient BMD hip and BMI
Infrared spectroscopy, histomorphometry,
and BMD hip

0.60
0.70
0.86
0.88

0.63
0.72
0.85
0.84

0.67
0.82
0.96
0.91

0.56
0.56
0.74
0.76

0.61
0.66
0.83
0.82

0.60
0.67
0.80
0.80

0.70
0.88
0.96
0.92

0.65
0.76
0.87
0.85

0.88

0.87

0.93

0.82

0.86

0.84

0.92

0.87

0.89

0.87

0.84

0.92

0.87

0.93

0.82

0.87

0.90

0.88

0.83

0.96

0.89

0.96

0.80

0.87

AUC = area under the receiver operating characteristic curve; BMI = body mass index; BMD = bone mineral density.
F-1 denotes the harmonic mean of precision and sensitivity. Boldface denotes the parameters associated with optimal machine-learning performance of
the duration model.

Fig 3. Relative importance and relationship of various bone relevant parameters to bisphosphonate treatment duration as determined by the machinelearning model. This model is referred to in the text as the “duration model.” Length of the horizontal bars denotes the magnitude of the linear coefﬁcient
in the machine-learning duration model; direction and color of the bars denote the sign of the coefﬁcient. Red bars extending to the left denote coefﬁcients negatively correlated with increasing bisphosphonate treatment duration; teal bars extending to the right denote coefﬁcients positively correlated
with increasing bisphosphonate treatment duration.

JBMR® Plus

BISPHOSPHONATE AND BONE QUALITY IN FRACTURES

5 of 10

n

Fig 4. (A) Images from FTIR examination of prepared trabecular bone surfaces. These images colorimetrically depict varying carbonate to phosphate
ratios in individual 6 μm  6 μm square areas of trabecular bone surface. Greater color intensity denotes bone surfaces with greater values of the carbonate to phosphate ratio. These images were obtained from different study patients each aged 59 years. The left image was obtained from a patient treated
with bisphosphonates for 3 years, the right image from a patient treated for 10 years. The image from the longer bisphosphonate treatment duration
shows more pixels with greater carbonate to phosphate ratio. (B) Images from FTIR examination of prepared trabecular bone surfaces. These images colorimetrically depict varying carbonate to phosphate ratios in individual 6 μm  6 μm square areas of trabecular bone surface. Greater color intensity
denotes bone surfaces with greater values of the carbonate to phosphate ratio. These images were obtained from different study patients each aged
59 years. The left image was obtained from a patient treated with bisphosphonates for 3 years, the right image from a patient treated for 10 years.
The image from the longer bisphosphonate treatment duration shows more pixels with greater carbonate to phosphate ratio.

fracture was modeled as a function of both categorical and continuous bisphosphonate treatment duration, and bone quality
measured using infrared spectroscopic, histomorphometric,
and patient-related parameters. The AUC metric was again used
to determine the parameters that provide the best ﬁt with fracture (Table 7). Optimum model performance (AUC = 0.88) for
overall ﬁt to the presence or absence of bone fractures was
obtained when bisphosphonate treatment duration (continuous
variable) and bone-quality parameters (infrared spectroscopic
and histomorphometric) were included in the model (Table 7).
This model was dominated by bisphosphonate treatment duration (continuous) and the infrared spectroscopic bone-quality
parameters; inclusion of the histomorphometric parameters contributed little to the model.
Nine parameters in the fracture model had estimated linear
coefﬁcients exceeding 0.2 (Fig. 6). These were included in the
machine-learning model relating bone fracture to continuous
bisphosphonate treatment duration, infrared spectroscopic,
and histomorphometry-based bone-quality parameters. The
important role of bone mineralization in this fracture model is
reﬂected by the fact that six of these nine parameters are mineral
related. Parameters associated with an increasing likelihood of
bone fracture were (in decreasing order of importance):
increased bisphosphonate treatment duration, increased carbonate substitution for phosphate in bone mineral, increased
collagen maturity, increased mineralization, decreased
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mineralization distribution, and increased mineral crystal length.
Hip BMD and patient age were not critical parameters in the fracture model. Details regarding the estimated linear coefﬁcients of
all parameters analyzed relative to bone fractures are provided in
Supplemental Fig. S2.

4.

Discussion

New information is provided guiding use of continuous oral
bisphosphonate treatment for postmenopausal osteoporosis,
supporting prior work citing the usefulness of infrared spectroscopy to evaluate bone quality. This demonstrates the clinical relevance of bone mineral quality.
Relationships between bone-quality parameters and bisphosphonate use were manifested by machine-learning analyses
only when duration was analyzed as a two-category (1 to 8 and
9 to 14 years) variable but not as a continuous variable. This
may be explained by bone quality, which changes positively with
bisphosphonate use for up to 8 years of treatment, but after this
period it changes negatively with continuing bisphosphonate
use. This explanation is consistent with our prior ﬁnding showing
increases in trabecular architecture-based strength estimates
occurring at approximately 7.5 years of bisphosphonate use,
then decreases in trabecular architecture-based strength occur
with continuing use.(8) It is noteworthy that these similar
JBMR Plus (WOA)

Fig 5. (A) Images from FTIR examination of prepared trabecular bone surfaces depicting ratios of mature to immature collagen cross-links. Darker colors
represent bone surfaces with greater ratios of mature to immature collagen cross-links. Both images were obtained from study patients aged 63 years. The
left image was obtained from a patient treated with bisphosphonates for 4 years, the right image from a patient treated for 12 years. The image from the
patient treated for 12 years shows an increased ratio of mature to immature collagen cross-links. (B) Images from FTIR examination of prepared trabecular
bone surfaces depicting ratios of mature to immature collagen cross-links. Darker colors represent bone surfaces with greater ratios of mature to immature collagen cross-links. Both images were obtained from study patients aged 63 years. The left image was obtained from a patient treated with bisphosphonates for 4 years, the right image from a patient treated for 12 years. The image from the patient treated for 12 years shows an increased ratio of
mature to immature collagen crosslinks.

Table 5. Pertinent Characteristics of Patients Who Fractured While on Bisphosphonate Treatment (n = 22)
Age at time of biopsy (years)
BMD hip (t value)
Body mass index
Duration of treatment (years)

Mean

Standard deviation

Median

Minimum

Maximum

61
1.90
25.57
7.28

9
0.77
4.83
3.36

61.50
1.90
25.49
6.50

34.00
3.50
18.75
2.50

77.00
0.50
33.80
14.00

BMD = bone mineral density.

Table 6. Pertinent Characteristics of Patients Who Did Not Fracture While on Bisphosphonate Treatment (n = 45)
Mean
Age at time of biopsy (years)
BMD hip (t value)
Body mass index
Duration of treatment (years)

Standard deviation

59
1.90
25.06
4.81

8
0.93
5.43
2.35

Median

Minimum

59
2.10
23.74
4.00

39
4.10
15.96
1.00

Maximum
77
1.00
43.53
11.33

BMD = bone mineral density.

treatment durations, ie, 7.5 and 8 years, were discovered using
different techniques quantifying different bone-quality parameters.(8) The observed 8-year time point in the present duration
model offers valuable new information identifying a treatment
period after which adverse changes to bone, including atypical
fractures, occur. This is consistent with observations from prior
studies.(11,27,28)
JBMR® Plus

Machine-learning analyses demonstrated the importance of
bone quality and underscore previous work noting the usefulness of infrared spectroscopy for assessing bone-quality
changes.(12,13,29) Speciﬁcally, four of the seven largest linear coefﬁcients in the duration model and six of the eight largest linear
coefﬁcients in the fracture model were bone-quality parameters
obtained from infrared spectroscopy. The relationship between
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Table 7. Results of Candidate Machine-Learning Models Relating Bone Fractures in Patients Receiving Bisphosphonate Treatment to Various Parameter Types
Model ﬁt
parameters

No fracture

Fracture

Parameter type

AUC

Accuracy

Precision

Sensitivity

F-1

Precision

Sensitivity

F-1

Histomorphometry
Duration (categorical)
Duration (continuous)
Infrared spectroscopy
Infrared spectroscopy and histomorphometry
Infrared spectroscopy and duration
(continuous)
Infrared spectroscopy and
histomorphometry and duration
(continuous)

0.44
0.60
0.72
0.78
0.86
0.86

0.55
0.84
0.71
0.74
0.81
0.78

0.67
0.81
0.77
0.90
0.88
0.86

0.58
1.00
0.73
0.65
0.79
0.77

0.55
0.89
0.75
0.76
0.84
0.81

0.47
1.00
0.62
0.62
0.73
0.70

0.50
0.60
0.67
0.89
0.83
0.80

0.49
0.71
0.64
0.73
0.78
0.74

0.90

0.83

0.96

0.76

0.84

0.72

0.94

0.81

AUC = area under the receiver operating characteristic curve.
F-1 denotes the harmonic mean of precision and sensitivity. Boldface denotes the parameters associated with optimal machine-learning performance of
the fracture model.

Fig 6. Relative importance and relationship of various bone parameters to fracture in bisphosphonate-treated patients as shown in the machine-learning
model. This model is referred to in the text as the “fracture model.” Length of the horizontal bars denotes the magnitude of the linear coefﬁcient in the
machine-learning duration model; direction and color of the bars denote coefﬁcient sign. Red bars extending to the left denote coefﬁcients negatively
correlated with increasing likelihood of fracture; teal bars extending to the right denote coefﬁcients positively correlated with increasing likelihood of
fracture.

bone quality and bisphosphonate treatment was observed not
just for changes in mean values of some bone-quality parameters but also in the distributions of these parameters. The latter
was previously shown in a study demonstrating changes in heterogeneity of bone-quality parameters with bisphosphonate
treatment duration.(12) The present study’s novel application of
machine-learning methods for the holistic analysis of the large
volume and variety of analyzed bone-quality parameters conﬁrmed prior ﬁndings and identiﬁed signiﬁcant new relationships
between mean values and distributions of bone-quality parameters with bisphosphonate treatment duration.
Bone mineral purity, measured using the carbonate to phosphate ratio, was the most signiﬁcant bone-quality parameter in
the bisphosphonate treatment duration machine-learning
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model. This ratio quantiﬁes the relative amount of carbonate
substituted for phosphate in bone mineral crystal. Increases in
this ratio with increasing bisphosphonate treatment duration
may be a consequence of reduced bone turnover, resulting in
older bone, longer-lived mineral, and thus more time for carbonate to substitute for phosphate in the mineral crystal structure.
The importance of the carbonate to phosphate ratio in the duration and fracture machine-learning models is underscored by
publications investigating relationships among bone quality,
hormone replacement therapy, as well as proximal femoral and
low-energy fractures.(13,30,31)
The second most signiﬁcant parameter in the duration model
was the decrease in standard deviation of bone with low collagen maturity. Thus, with increasing bisphosphonate treatment
JBMR Plus (WOA)

duration, the range of values for the ratio of mature to immature
collagen cross-links decreased. As expected, the duration model
showed that hip BMD was a signiﬁcant parameter (third in
importance) directly related to bisphosphonate treatment duration. This is consistent with increased mineralization observed in
a prior study of 32 postmenopausal women with osteoporosis
treated with bisphosphonates for 6.4  2.0 years.(32) The fourth
and ﬁfth most signiﬁcant parameters of the model indicate that
fewer osteoclasts and reduced activation frequency accompany
longer bisphosphonate treatment durations. These ﬁndings are
consistent with the known effect of bisphosphonates on bone
turnover(33,34) and with the reported 84% reduction in remodeling activity observed in iliac crest bone samples from the previously cited study.(32) The previously shown increase in mineral
to matrix ratio with increasing bisphosphonate treatment duration(12) was conﬁrmed by the present study but was ranked
11th of the 15 duration-model analyzed parameters.
The machine-learning fracture model showed that bisphosphonate treatment duration was the most important feature
predictive of the observed low-energy fractures, ie, longer
bisphosphonate treatment duration was associated with greater
likelihood of fracture. This ﬁnding agrees with a study of 196,129
postmenopausal women treated with bisphosphonates showing
that compared with women treated for 3 to 5 years, treatment
for 8 or more years was associated with an almost ﬁvefold
increase in hazard ratio for atypical fractures.(27)
Relevance of bone mineral purity, quantiﬁed by the carbonate
to phosphate ratio, was demonstrated by this parameter’s rank
(second most important) in the fracture machine-learning
model. This ﬁnding is supported by a study of 60 bisphosphonate-naive female patients with fractures who had decreased
carbonate to phosphate ratios in iliac crest cancellous bone compared with 60 sex-, age-, and BMD-matched controls.(13) Differences in the direction of the relationships observed in these
studies may be explained by the different patient populations.
Relative bone mineralization, quantiﬁed by the mineral-tomatrix quality parameter, was the third most important parameter in the machine-learning fracture model. Thus, the likelihood
of low-energy fracture in patients treated long term with bisphosphonates is directly related to increased relative bone mineralization. This ﬁnding is consistent with data showing that
increased mineralization is associated with decreased fracture
toughness.(35)
Bisphosphonate treatment is associated with increased hip
BMD and consequentially reduction in fracture risk.(36) Although
hip BMD was the third most important parameter in the duration
model and was directly related to bisphosphonate use, hip BMD
was not among the top 25 parameters in the fracture model. This
ﬁnding suggests that the low-energy fractures in study patients
treated with bisphosphonates for more than 8 years are those
due to diminished bone quality and turnover changes occurring
with long-term bisphosphonate use.
Among the many parameters studied, patient age was not a
signiﬁcant parameter in the treatment duration or fracture
models. Spine BMD was not included among the analyzed
parameters because of the inferior fracture predictive value of
spine BMD compared with hip BMD.(37,38)
Limitations of the study are those that are characteristic of a
cross-sectional design. In addition, most patients in the study
used alendronate, thus the analyses were unable to discern the
effect of other oral bisphosphonates. Inclusion of bone biopsies
in the study results in a study size that is small compared with
those of epidemiologic studies; however, the employed sample
JBMR® Plus

size is sufﬁcient to enable machine-learning analyses to identify
key bone-quality parameters and create models that signiﬁcantly relate these parameters to treatment duration and lowenergy fracture. We recognize that 22 fractures occurring in
67 patients on long-term bisphosphonate treatment is a relatively high percentage (32.8%); however, no selection bias can
be identiﬁed to explain this result.
Continuous use of oral bisphosphonates exceeding 8 years is
associated with signiﬁcant declines in bone mineral quality and
increases in low-energy bone fractures. These ﬁndings provide
evidence for an 8-year maximum time limit for uninterrupted
treatment. Bone quality is an important aspect of skeletal health
and should be considered when evaluating the efﬁcacy of various bone metabolic therapies. Inadequate bone quality is related
to increased likelihood of low-energy fracture. Infrared spectroscopic examination of biopsied tissue samples provides critically
important, but otherwise unavailable, information describing
bone quality.
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